AIAxios1h ago
Mithrl, which integrates its proprietary biomedical world model
Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures
TL;DRAI startup Mithrl raised $20M to help drug companies use its biomedical AI model in their R&D.
Why it matters: AI-accelerated drug discovery could compress timelines and reduce costs for an industry that needs both.
Mithrl, an AI infrastructure company for biopharma, raised a $20 million Series A, CEO Vivek Adarsh tells Axios exclusively.
Read full articleSource: Axios · Opens in new tab